The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers c4 therapeutics price target while maintaining neutral rating
UBS has lowered its price target for C4 Therapeutics, Inc. to $3.50 from $4 while maintaining a neutral rating. The clinical-stage biopharmaceutical company focuses on targeted protein degradation, utilizing its TORPEDO platform to develop small-molecule medicines, including candidates CFT7455 and CFT1946 for various cancers.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.